Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Similar documents
CEREBRO VASCULAR ACCIDENTS

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Dental Management Considerations for Patients on Antithrombotic Therapy

Prostate Biopsy Alerts

GERIATRICS CASE PRESENTATION

Hit head, on blood thinner-wife wants CT. Will Davies June 2014

Position statement: Anti-coagulants and Risk Assessment

Should We Reconsider using Anticoagulation for Biological Tissue Valves

Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective

EVIDENCE ON MINOR HEAD INJURY IN GERIATRICS. Janet Talbot-Stern, FACEM, FRCEM, FACEP

Is Stroke Frequency Declining?

Index. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

NeuroPI Case Study: Anticoagulant Therapy

New Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice

Supplementary Online Content

Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?

Yes No Unknown. Major Infection Information

Manuel Castella MD PhD Hospital Clínic, University of

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Primary Stroke Center Quality & Performance Measures

Apixaban for stroke prevention in atrial fibrillation. August 2010

Guideline for Treatment of Head Injury in the Anticoagulated Patient

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency

Slide 1: Perioperative Management of Anticoagulation

2.5 Other Hematology Consult:

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

Stroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013

Durlaza. Durlaza (aspirin) Description

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Retrospective Study on the Safety and Efficacy of Clopidogrel in the Treatment of Acute Cerebral Infarction

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease

Preoperative Management of Patients Receiving Antithrombotics

Pharmacy STROKE. Anne Kinnear Lead Pharmacist NHS Lothian. Educational Solutions for Workforce Development

Multidisciplinary Geriatric Trauma Care Guideline

Clinical Practice Guideline for Anticoagulation Management

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

TRAUMATIC CAROTID &VERTEBRAL ARTERY INJURIES

PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016

HEART HEALTH WEEK 2 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease ATHEROSCLEROSIS. Fatty deposits can narrow and harden the artery

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

American College of Cardiology 66th Annual Scientific Session (ACC.17):

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely

Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study

When and how to combine antiplatelet agents and anticoagulant?

'VENICE'ARRYTHMIAS'2015'' Venice,'17 th 'October'2015''

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called

Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

Asif Serajian DO FACC FSCAI

M. Edip Gurol, MD, MSc Stroke Service/Neurology, Massachusetts General Hospital, Harvard Medical School

CEDR 2018 QCDR Measures for CMS 2018 MIPS Performance Year Reporting

The randomized study of efficiency and safety of antithrombotic therapy in

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE. Cranial Health History Form

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

Drug Class Monograph

YES. Your Guide to Getting WATCHMAN. Is a life without blood thinners possible?

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Drug Class Review Newer Oral Anticoagulant Drugs

Robert Moesinger MD--Moderator Joe Hansler MD--Surgery Justin Mansfield MD Internal Medicine Charles Ivester MD, PHD Pulmonology/Critical Care John

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

Kadlec Regional Medical Center Cardiac Electrophysiology WATCHMAN Left Atrial Appendage Closure Device

Xarelto (rivaroxaban) Prescriber Guide

Michael Horowitz, MD Pittsburgh, PA

Section Editor Scott E Kasner, MD

PROPOSAL FOR MULTI-INSTITUTIONAL IMPLEMENTATION OF THE BRAIN INJURY GUIDELINES

How Long Patietns Will Be on Dual Antiplatelet Therapy?

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health

TIA: Updates and Management 2008

Do Not Cite. Draft for Work Group Review.

5/15/2018. Reduced Platelet Activity

Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

Primary Care practice clinics within the Edmonton Southside Primary Care Network.

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Listen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need

Supplementary Online Content

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

Anti-thromboticthrombotic drugs

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial

ADULT CARDIAC SURGERY TELEMETRY BED TRANSFER ORDERS 1 of 4

Protocol for IV rtpa Treatment of Acute Ischemic Stroke

Eliquis and plavix combination therapy

Transcription:

Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Common Anticoagulants and Indications Coumadin (warfarin) indicated for venous thrombosis, pulmonary embolism, atrial fibrillation, cardiac valve replacement, reduce risk of recurrent myocardial infarction and stroke. Aspirin indicated for treatment of pain/inflammation from arthritis, soft tissue injuries, pain, fever, and to decrease risk of recurrent stroke, transient ischemic attack (TIA) and myocardial infarction. Lovenox indicated for deep vein thrombosis, unstable angina, and myocardial infarction. Plavix indicated to reduce thrombotic events such as myocardial infarction, stroke, peripheral vascular disease and acute coronary syndrome.

We Have Noted Lutheran General Trauma Department has identified over the last 6 months an increase in mortality due to falls with head injuries for pt on anticoagulants. Did you know? According to the CDC, a person > 65 years of age dies every 35 minutes due to complications from a fall.

Physiologic Changes As we age, our brains lose mass which allows for increased movement within the skull with any kind of trauma. There is an increased subdural space more room for bleeding.

Mechanism of Injury Even with minor head trauma, the pt on an anticoagulant is at great risk for a significant head injury. Especially at risk: unwitnessed falls.

Possible Injuries Subdural bleed Intracerebral bleed Epidural bleed

Facts Anticoagulated patients have increased risk for bleeding, and serious outcomes could occur after head injury. Traumatic brain injury results in just over 1.3 million ED visits in USA. In elderly patients suffering a fall, long-term anticoagulation has been shown to increase not only the incidence of ICH compared to those not on anticoagulation (8.0% vs. 5.3%, p < 0.0001), but to also increase mortality in those with ICH (21.9% vs. 15.2%, p = 0.04)

Facts Clinical decision rules such as the Canadian CT Head Rule, the New Orleans criteria, and the NEXUS-II criteria exist to help determine which head injury patients require a head CT scan, these rules do not apply to anticoagulated patients

Facts Studies in patients taking warfarin who suffer minor head injury have shown incidences of ICH ranging from 6.2% to 29%, leading some authors to conclude that most, if not all, such patients should undergo routine cranial CT scanning on presentation.

Facts European guidelines suggest that all anticoagulated patients with head injury should be admitted for a period of routine observation, these recommendations are not based on studies of the prevalence of delayed ICH

Questions we need to ask?? Can Anticoagulated Patients Be Discharged Home Safely From the Emergency Department After Minor Head Injury? What is the risk of delayed ICH in anticoagulated patients with minor head injury and a normal initial head CT scan?

In the four studies reviewed, the incidence of delayed ICH after normal CT scan ranged from 0.6% to 6%. Clinically significant ICH requiring neurosurgical intervention is rare and ranged from 0 to 1.1%

The incidence of death or neurosurgical intervention ranged from 0 to 1.1%. Another retrospective study of 1493 patients admitted for traumatic brain injury with preinjury warfarin use showed that both the risk of ICH and mortality were increased with higher INR.(INR 2.0. other study INR 3 )

The risk of major bleeding is known to increase for those on combined anticoagulant antiplatelet therapy, with hazard ratios of 1.83 (95% CI 1.72 1.96) and 3.08 (95% CI 2.32 3.91) for combined warfarin aspirin and warfarin clopidogrel use, respectively, compared to warfarin therapy alone

it is estimated that 24-h observation and repeat CT scan would cost over 1 million dollars per patient undergoing neurologic intervention.

Clinical Take Home Points Routine head CT in head-injured patients with previous warfarin or clopidogrel use should be performed, even in wellappearing patients regardless of lack of clinical findings

Clinical Take Home Points Delayed traumatic ICH in patients on therapeutic warfarin and clopidogrel is very rare and these patients may be discharged home after a negative initial head CT, but with explicit discharge instructions and close follow up

Clinical Take Home Points 24 hour observation of patients with poor functional capacity, long travel times to get to a hospital, and/or patients with no one at home to watch them would also be an acceptable alternative

Clinical Take Home Points Patients with therapeutic anticoagulation, blunt head trauma, and a negative initial head CT DO NOT need to have their anticoagulation aggressively reversed

Patients with supratherapeutic anticoagulation, blunt head trauma, and a negative initial head CT, I would have a low threshold to admit them for frequent neuro checks, repeat measurement of INR (while holding anticoagulation), and possibly repeat head CT if any change in exam

What Do We Do At the Hospital? Stop the bleeding! With a patient on coumadin, within one hour of positive CT scan we administer fresh frozen plasma and vitamin K. With a patient on aspirin, within one hour of positive CT scan we administer platelets. We have an extensive 2 page guideline for reversal of anticoagulants.

In Conclusion Identified high risk patients (age > 65, INR >3, Combined ASA with warfarin Order CT head even Normal Nuerogical exam 24 h observation in hospital depend on your judment Dealyed ICH is rare but need good instruction

Any Questions???